(Thomas Fuller/Getty Images)

Hims & Hers to sell Eli Lilly’s Zepbound on its platform

Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs is over.

4/1/25 2:16PM

Hims & Hers shares rose Tuesday afternoon after the telehealth company said it would offer Eli Lilly’s blockbuster weight-loss drug Zepbound on its platform.

The move gives Hims & Hers a way to offer its users the cutting edge of popular weight-loss drugs after the FDA severely limited Hims’ ability to produce them itself. On February 21, the Food and Drug Administration announced an end to the shortage of semaglutide, the active ingredient in Ozempic and Wegovy, drugs made by Novo Nordisk. Hims & Hers made about $230 million selling compounded semaglutide in 2024. The company has never sold compounded tirzepatide, the active ingredient in Zepbound.

Hims & Hers users can now get a prescription for Zepbound on the platform, but not at a discount: it costs about $1,899 a month, according to the company’s website. Sometimes insured customers can be reimbursed for the drug. For comparison, Lilly offers Zepbound to uninsured patients for about $500 a month, and compounded semaglutide costs about $200 a month.

Shares initially jumped sharply on the news, but gains faded in the afternoon as investors parsed the news.

Hims & Hers’ share price tanked after the FDA announcement on February 21, as it became unclear to what extent the company could continue making money selling GLP-1 drugs. Even with the recent boost, which faded hours later, Hims & Hers is still significantly down since the FDA called off the shortage.

The company has previously said that it would sell generics of Novo’s older weight-loss drugs and “personalized” doses of semaglutide. “We’re committed to bringing our customers more treatment options that best suit their needs, and we’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said in its announcement.

Lilly has struck deals to sell discounted vials of Zepbound on Ro, a privately held Hims & Hers competitor, and Amazon Pharmacy. Novo has launched its own direct-to-consumer platform to sell discounted Wegovy to patients without insurance.

Tasha Matsumoto, Matt Phillips

4/17/26

The S&P 500, Nasdaq 100, and Russell 2000 close at record highs again as Strait of Hormuz is declared open

Stocks reached new record highs as risk-on sentiment flooded back into the markets, while oil tumbled.

Chicago Bulls players Dennis Rodman (L), Scottie Pippen (C) and Michael Jordan (R) hold three of the team's four recent Larry O'Brien trophies 18 June at a rally for the team in Grant Park in Chicago.

Matt Phillips4/17/26

With their recent surge, Intel shares just hit their highest level since the dot-com era

Intel’s surge of nearly 60% this month has the iconic American chipmaker’s stock price approaching levels last seen during the dot-com era. Bloomberg noted that shares just touched their highest intraday level since the turn of the century:

“The stock rose as much as 1.5% to $69.55, topping a peak it hit on Jan. 24, 2020. The shares are up 90% this year, after soaring 84% in 2025. Intel is now roughly 8% from its all-time closing high of $74.88, established on Aug. 31, 2000.”

That’s just the most recent late-’90s-era throwback we’ve been seeing in tech shares lately. Oracle is currently pacing for its best week since late 1999.

What’s even more remarkable, however, is that Intel’s forward price-to-earnings ratio today dwarfs the premiums the market was putting on the stock during the nuttiness of the dot-com mania.

That reflects the fact that the recent run-up in Intel shares is, essentially, giving the chip giant credit for a massive turnaround that hasn’t actually happened yet.

One also might wonder if the fact that Intel is partially owned by the US government means it’s more attractive — and therefore worth a higher premium — than other chipmakers without the state imprimatur.

Still, kind of startling.

Jake Paul v Anthony Joshua - Fighter Showcase & Open Workout

Netflix sinks following disappointing outlook as investors wait for more ad growth

Netflix shares are down more than 10% on Friday morning.

Max Knoblauch4/17/26

J. Edward Moreno4/17/26

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Eli Lilly makes the world’s bestselling drug. Can it keep the party going?

Claire Yubin Oh4/17/26

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a “150-tonne bulk sample program,” which is slated for June 2026.